Table 1 Patient and tumour characteristics at baseline (intent-to-treat population)
From: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Tumour type | |||
|---|---|---|---|
Characteristics | Non-gallbladder ( n =45) | Gallbladder ( n =25) | All ( n =70) |
Gender, no. (%) | |||
Male | 22 (48.9) | 6 (24.0) | 28 (40.0) |
Female | 23 (51.1) | 19 (76.0) | 42 (60.0) |
Median age, years (range) | 62 (30–83) | 55 (30–72) | 62 (30–83) |
ECOG PS, no. (%) | |||
0 | 23 (51.1) | 12 (48.0) | 35 (50.0) |
1 | 21 (46.7) | 10 (40.0) | 31 (44.3) |
2 | 1 (2.2) | 3 (12.0) | 4 (5.7) |
Primary tumour location, no. (%) | |||
Gallbladder | 0 (0.0) | 25 (100.0) | 25 (35.7) |
Intrahepatic bile ducts | 30 (66.7) | 0 (0.0) | 30 (42.9) |
Extrahepatic bile ducts | 13 (28.9) | 0 (0.0) | 13 (18.6) |
Intra/extrahepatic bile ducts | 1 (2.2) | 0 (0.0) | 1 (1.4) |
Ampulla of Vater | 1 (2.2) | 0 (0.0) | 1 (1.4) |
Prior treatment for BTC, no. (%) | |||
Surgery | 18 (40.0) | 20 (80.0) | 38 (54.3) |
Radiotherapy | 0 (0.0) | 1 (4.0) | 1 (1.4) |
Disease status, no. (%) | |||
Metastatic | 32 (71.1) | 19 (76.0) | 51 (72.9) |
Locally advanced | 13 (28.9) | 6 (24.0) | 19 (27.1) |
